RCM
ODT

RA Capital Management’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

RA Capital Management’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-200,000
Closed -$5.21M – 40
2019
Q3 		$5.21M Hold
200,000
– – 0.31% 29
2019
Q2 		$7.34M Buy
+200,000
New +$4.79M 0.39% 25

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

RA Capital Management's ODT Position: Q4 2019 in Review

RA Capital Management sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q4 2019, closing a stake of 200,000 shares — an estimated $5.21M sold.

RA Capital Management first reported a position in ODT in Q2 2019 and held it in 2 quarters. The position peaked at $7.34M in Q2 2019. 88 funds tracked by Wall St. Rank hold ODT as of Q4 2019.

  • RA Capital Management reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • RA Capital Management sold 200,000 Odonate Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $5.21M.
  • RA Capital Management first reported a position in Odonate Therapeutics, Inc. Common Stock in Q2 2019 and held it in 2 quarters.
  • RA Capital Management's Odonate Therapeutics, Inc. Common Stock position peaked at $7.34M in Q2 2019.
  • 88 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q4 2019.

Based on RA Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.